Table 3.
Univariate logistic regression between immunohistochemistry results and clinical and pathological variables in PC patients.
| ATPLy + vs. − (OR 95% CI) |
CPT1a, + vs. − (OR 95% CI) |
SCD + vs. − (OR 95% CI) |
SREBP + vs. − (OR 95% CI) |
FAS + vs. − (OR 95% CI) |
AC-1 + vs. − (OR 95% CI) |
|
|---|---|---|---|---|---|---|
| PSA, continuous | 1.01 (0.98–1.03) | 1.00 (0.97–1.02) | 0.98 (0.95–1.01) | 0.96 (0.92–1.00) | 1.00 (0.98–1.03) | 0.99 (0.97–1.01) |
| Fasting blood glucose, continuous | 0.99 (0.98–1.01) | 1.00 (0.99–1.02) | 0.99 (0.98–1.01) | 1.00 (0.99–1.01) | 0.99 (0.98–1.00) | 0.99 (0.98–1.01) |
| Total cholesterol, continuous | 0.99 (0.98–1.00) | 0.99 (0.98–1.01) | 0.99 (0.98–1.00) | 0.99 (0.98–1.00) | 0.99 (0.99–1.00) | 0.99 (0.98–1.00) |
| Triglycerides, continuous | 1.00 (0.99–1.01) | 1.00 (0.99–1.01) | 0.99 (0.98–1.00) | 0.99 (0.98–1.00) | 0.99 (0.99.1.00) | 0.99 (0.98–1.00) |
| Diabetes, yes vs. no | 1.11 (0.58–2.16) | 0.82 (0.49–2.43) | 1.58 (0.74–3.39) | 0.51 (0.22–1.21) | 0.50 (0.26–0.97) | 1.60 (0.83–3.06) |
| Pathological stage, pT3/4 vs. pT2 | 1.27 (0.76–2.12) | 1.08 (0.79–2.04) | 0.94 (0.49–1.80) | 1.04 (0.60–1.85) | 0.71 (0.42–1.20) | 1.30 (0.93–1.80) |
| ISUP Gleason, ≥4 vs. <4 | 1.82 (0.77–4.30) | 0.75 (0.44–3.02) | 1.53 (0.61–3.82) | 0.79 (0.30–2.04) | 1.47 (0.60–3.60) | 1.21 (0.98–1.52) |
| AR, + vs. − | 1.71 (1.06–2.77) † | 2.27 (1.24–4.16) † | 2.87 (1.53–5.39) † | 2.16 (1.25–3.73) † | 2.19 (1.30–3.69) † | 3.65 (2.22–5.93) † |
| PSMA, + vs. − | 1.12 (0.70–1.80) | 0.97 (0.54–1.75) | 1.16 (0.64–2.12) | 0.94 (0.55–1.61) | 1.64 (1.00–2.71) † | 1.80 (1.13–2.89) † |
| Ki-67, + vs. − | 1.33 (0.71–2.50) | 1.37 (0.66–2.84) | 2.16 (1.07–4.32) † | 1.02 (0.51–2.04) | 1.67 (0.83–3.38) | 1.11 (0.60–2.03) |
| IR-α, + vs. − | 2.56 (1.43–4.56) † | 2.55 (1.03–6.27) † | 1.20 (0.56–2.56) | 1.93 (0.92–4.05) | 3.31 (1.84–5.95) † | 9.99 (4.35–22.93) † |
| IR-β, + vs. − | 1.08 (0.45–2.59) | 2.45 (1.01–6.11) † | 1.24 (0.44–3.51) | 1.33 (0.52–3.38) | 1.77 (0.63–4.95) | 1.85 (0.77–4.43) |
| IGF-1R, + vs. − | 1.30 (0.73–2.32) | 0.96 (0.47–1.95) | 1.01 (0.49–2.07) | 0.35 (0.16–0.78) † | 0.80 (0.44–1.44) | 1.18 (0.67–2.05) |
| ATPLy + vs. − | - | 1.26 (0.69–2.32) | 1.43 (0.76–2.68) | 1.41 (0.81–2.47) | 4.84 (2.84–8.25) † | 4.97 (2.95–8.39) † |
| CPT1a, + vs. − | 1.26 (0.69–2.32) | - | 2.15 (1.08–4.24) † | 2.95 (1.58–5.49) † | 2.16 (1.05–4.41) † | 2.12 (1.16–3.87) † |
| SCD + vs. − | 1.43 (0.76–2.68) | 2.15 (1.08–4.24) † | - | 2.87 (1.53–5.39) † | 3.17 (1.42–7.04) † | 2.63 (1.40–4.91) † |
| SREBP + vs. − | 1.41 (0.81–2.47) | 2.95 (1.57–5.48) † | 2.87 (1.53–5.39) † | - | 1.74 (0.94–3.21) | 2.53 (1.45–4.40) † |
| FAS + vs. − | 4.84 (2.84–8.25) † | 2.16 (1.05–4.41) † | 3.17 (1.42–7.04) † | 1.74 (0.94–3.21) | - | 11.29 (5.76–22.14) † |
OR = odds ratio; CI = confidence interval; PSA = prostate-specific antigen; ISUP = International Society of Urological. Pathology; AR = androgen receptor; PSMA = prostate specific antigen; IR = insulin receptor; IGF-1R = insulin growth factor-1 receptor; ATPLy = ATP lyase; CPT = Anti-carnitine palmitoyl transferase; SCD = Stearoyl-CoA desaturase-1; SREBP = Sterol regulatory element-binding protein; FAS = fatty acid synthase; AC-1 = Acetyl-CoA Carboxylase-1; † p < 0.05.